Improving Access to Abortion in the Republic of Georgia
NCT ID: NCT04458558
Last Updated: 2020-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
120 participants
INTERVENTIONAL
2020-06-30
2021-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acceptability and Feasibility of a Simplified Medical Abortion Regimen in Georgia
NCT02398838
Acceptability and Feasibility of a Demedicalized Medical Abortion Regimen in the Caucasus
NCT02219100
Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy in Armenia
NCT01766388
Simplifying First Trimester Medical Abortion Follow-up
NCT03014193
A Randomized Study of Cervical Priming With Misoprostol Prior to Elective First Trimester Pregnancy Termination
NCT00310921
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Medical abortion patients
Oral mifepristone 200 mg followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone).
Mifepristone
Participants will receive mifepristone at a preferred address by mail rather than standard care at clinic visit.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mifepristone
Participants will receive mifepristone at a preferred address by mail rather than standard care at clinic visit.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eligible for medical abortion according to study provider's assessment
* Able to receive physical mail
* Have access to a phone
* Be willing and able to consent to participate in the study
* Be willing to follow study procedures
Exclusion Criteria
* Contraindications to medical abortion
16 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gynuity Health Projects
OTHER
Healthy Life
UNKNOWN
Grand Challenges Canada
OTHER
Center for Information and Counseling on Reproductive Health - Tanadgoma
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Batumi Medical Center
Batumi, , Georgia
David Gagua Clinic
Tbilisi, , Georgia
Clinic Elite
Zestaponi, , Georgia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Temur Gabaidze, MD
Role: primary
George Tsertsvadze, MD
Role: primary
Kote Bochorishvili, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2.1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.